Literature DB >> 28632965

Frequent COL4 mutations in familial microhematuria accompanied by later-onset Alport nephropathy due to focal segmental glomerulosclerosis.

L Papazachariou1, G Papagregoriou1, D Hadjipanagi1, P Demosthenous1, K Voskarides1, C Koutsofti1, K Stylianou2, P Ioannou2, D Xydakis2, I Tzanakis3, A Papadaki3, N Kallivretakis3, N Nikolakakis4, G Perysinaki4, D P Gale5, A Diamantopoulos6, P Goudas7, D Goumenos8, A Soloukides9, I Boletis10, C Melexopoulou10, E Georgaki11, E Frysira12, F Komianou13, D Grekas14, C Paliouras15, P Alivanis15, G Vergoulas16, A Pierides1,17, E Daphnis2, C Deltas1.   

Abstract

Familial microscopic hematuria (FMH) is associated with a genetically heterogeneous group of conditions including the collagen-IV nephropathies, the heritable C3/CFHR5 nephropathy and the glomerulopathy with fibronectin deposits. The clinical course varies widely, ranging from isolated benign familial hematuria to end-stage renal disease (ESRD) later in life. We investigated 24 families using next generation sequencing (NGS) for 5 genes: COL4A3, COL4A4, COL4A5, CFHR5 and FN1. In 17 families (71%), we found 15 pathogenic mutations in COL4A3/A4/A5, 9 of them novel. In 5 families patients inherited classical AS with hemizygous X-linked COL4A5 mutations. Even more patients developed later-onset Alport-related nephropathy having inherited heterozygous COL4A3/A4 mutations that cause thin basement membranes. Amongst 62 heterozygous or hemizygous patients, 8 (13%) reached ESRD, while 25% of patients with heterozygous COL4A3/A4 mutations, aged >50-years, reached ESRD. In conclusion, COL4A mutations comprise a frequent cause of FMH. Heterozygous COL4A3/A4 mutations predispose to renal function impairment, supporting that thin basement membrane nephropathy is not always benign. The molecular diagnosis is essential for differentiating the X-linked from the autosomal recessive and dominant inheritance. Finally, NGS technology is established as the gold standard for the diagnosis of FMH and associated collagen-IV glomerulopathies, frequently averting the need for invasive renal biopsies.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Alport syndrome; COL4A3/COL4A4/COL4A5; end-stage renal disease (ESRD); familial microscopic hematuria; focal segmental glomerulosclerosis (FSGS); later-onset Alport-related nephropathy (LOAN); next generation sequencing; thin basement membrane nephropathy (TBMN)

Mesh:

Substances:

Year:  2017        PMID: 28632965     DOI: 10.1111/cge.13077

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  16 in total

Review 1.  Variations of type IV collagen-encoding genes in patients with histological diagnosis of focal segmental glomerulosclerosis.

Authors:  Erol Demir; Yasar Caliskan
Journal:  Pediatr Nephrol       Date:  2019-06-28       Impact factor: 3.714

2.  Prevalence of hereditary tubulointerstitial kidney diseases in the German Chronic Kidney Disease study.

Authors:  Bernt Popp; Arif B Ekici; Karl X Knaup; Karen Schneider; Steffen Uebe; Jonghun Park; Vineet Bafna; Heike Meiselbach; Kai-Uwe Eckardt; Mario Schiffer; André Reis; Cornelia Kraus; Michael Wiesener
Journal:  Eur J Hum Genet       Date:  2022-09-13       Impact factor: 5.351

3.  Promises and pitfalls of whole-exome sequencing exemplified by a nephrotic syndrome family.

Authors:  Mara Sanches Guaragna; Anna Cristina Gervásio de Brito Lutaif; Marcela Lopes de Souza; Andréa Trevas Maciel-Guerra; Vera Maria Santoro Belangero; Gil Guerra-Júnior; Maricilda Palandi de Mello
Journal:  Mol Genet Genomics       Date:  2019-09-13       Impact factor: 3.291

4.  Loss of the collagen IV modifier prolyl 3-hydroxylase 2 causes thin basement membrane nephropathy.

Authors:  Hande Aypek; Christoph Krisp; Shun Lu; Shuya Liu; Dominik Kylies; Oliver Kretz; Guochao Wu; Manuela Moritz; Kerstin Amann; Kerstin Benz; Ping Tong; Zheng-Mao Hu; Sulaiman M Alsulaiman; Arif O Khan; Maik Grohmann; Timo Wagner; Janina Müller-Deile; Hartmut Schlüter; Victor G Puelles; Carsten Bergmann; Tobias B Huber; Florian Grahammer
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

Review 5.  How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists.

Authors:  Aya Imafuku; Kandai Nozu; Naoki Sawa; Koichi Nakanishi; Yoshifumi Ubara
Journal:  Clin Exp Nephrol       Date:  2020-03-30       Impact factor: 2.801

6.  Features of Autosomal Recessive Alport Syndrome: A Systematic Review.

Authors:  Jiwon M Lee; Kandai Nozu; Dae Eun Choi; Hee Gyung Kang; Ii-Soo Ha; Hae Ii Cheong
Journal:  J Clin Med       Date:  2019-02-03       Impact factor: 4.241

7.  Autosomal dominant form of type IV collagen nephropathy exists among patients with hereditary nephritis difficult to diagnose clinicopathologically.

Authors:  Aya Imafuku; Kandai Nozu; Naoki Sawa; Eiko Hasegawa; Rikako Hiramatsu; Masahiro Kawada; Junichi Hoshino; Kiho Tanaka; Yasuo Ishii; Kenmei Takaichi; Takeshi Fujii; Kenichi Ohashi; Kazumoto Iijima; Yoshifumi Ubara
Journal:  Nephrology (Carlton)       Date:  2018-10       Impact factor: 2.506

8.  The importance of clinician, patient and researcher collaborations in Alport syndrome.

Authors:  Michelle N Rheault; Judith Savige; Michael J Randles; André Weinstock; Melissa Stepney; A Neil Turner; Gina Parziale; Oliver Gross; Frances A Flinter; Jeffrey H Miner; Sharon Lagas; Susie Gear; Rachel Lennon
Journal:  Pediatr Nephrol       Date:  2019-05-01       Impact factor: 3.714

9.  COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect?

Authors:  Konstantinos Voskarides; Gregory Papagregoriou; Despina Hadjipanagi; Ioanelli Petrou; Isavella Savva; Avraam Elia; Yiannis Athanasiou; Androulla Pastelli; Maria Kkolou; Michalis Hadjigavriel; Christoforos Stavrou; Alkis Pierides; Constantinos Deltas
Journal:  BMC Nephrol       Date:  2018-05-16       Impact factor: 2.388

10.  Should We Diagnose Autosomal Dominant Alport Syndrome When There Is a Pathogenic Heterozygous COL4A3 or COL4A4 Variant?

Authors:  Judy Savige
Journal:  Kidney Int Rep       Date:  2018-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.